DMT pharmacology (educational science)
Educational only. dmt.clinic is operated by AdvancedCare USA Inc. as a research reference. It is not a clinic, does not provide medical advice, does not refer patients, and does not sell substances or paraphernalia. N,N-DMT and 5-MeO-DMT are Schedule I controlled substances under the U.S. Controlled Substances Act (21 U.S.C. §812; 21 C.F.R. §1308.11; confirmed as of 2026-07-21). This page explains published pharmacology. It does not teach extraction, synthesis, brewing, administration, or dosing.
Indolealkylamine structure (why the names look similar)
N,N-dimethyltryptamine (N,N-DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are both tryptamine (indolealkylamine) molecules. They share a tryptamine backbone; they are not the same compound. A small structural difference (the 5-methoxy substitution on 5-MeO-DMT) is associated with a different balance of serotonin-receptor affinities and with different patterns in observational and experimental literature.
When people say “DMT” in casual speech they usually mean N,N-DMT. When they say “5-MeO” they mean a different research molecule. For a side-by-side educational comparison, see DMT vs 5-MeO-DMT.
Receptor pharmacology (what papers measure)
Classic serotonergic psychedelics are often discussed in terms of 5-HT2A receptor agonism. That framing is useful for N,N-DMT and remains part of how textbooks and reviews introduce the class — but it is incomplete for 5-MeO-DMT.
| Feature (research framing) | N,N-DMT (typical emphasis) | 5-MeO-DMT (typical emphasis) |
|---|---|---|
| Core class | Indolealkylamine psychedelic | Related tryptamine with distinct profile |
| 5-HT2A | High interest in binding/functional studies | Also engaged; not the whole story |
| 5-HT1A | Present in profiles | Often highlighted as especially important |
| Subjective research themes | Frequently more “visual” language in reports | Frequently more “ego-dissolution / intensity” language |
Receptor affinities are laboratory measurements (radioligand binding, functional assays). They are not dosing guidance and do not tell a layperson how a compound “should be taken.” Primary literature includes receptor-binding and review papers across decades; human experimental work on N,N-DMT includes the Strassman-era intravenous studies in the 1990s and later neuroimaging work (see clinical research).
Boundary: affinity tables and half-life numbers are not recipes. We do not convert receptor data into “how much,” “how long to wait,” or “what to combine.”
Metabolism and short duration (pharmacokinetics sketch)
Both compounds are rapidly metabolized relative to many other psychoactive drugs. Published human and preclinical work describes short plasma half-lives for N,N-DMT on the order of roughly 10–15 minutes in common experimental contexts (exact values depend on route, assay, and study design — always read the primary paper). 5-MeO-DMT is likewise short-acting in experimental descriptions.
Important educational points:
- Rapid clearance helps explain why some laboratory protocols use continuous intravenous infusion to sustain a measurable state for imaging (e.g., Imperial College continuous-infusion work summarized on our clinical research page) — that is a research method, not a public technique.
- Metabolism involves monoamine oxidase pathways among other enzymes; that is why oral N,N-DMT without monoamine-oxidase inhibition is generally described as having little or no classical oral psychoactivity in the ethnobotanical literature.
- Short duration does not mean “safe by default.” Cardiovascular and psychological adverse events still occur in uncontrolled settings.
MAO and ayahuasca (explanatory pharmacology, not a recipe)
Traditional ayahuasca is a brew, not a single pure molecule. Ethnographic and pharmacological literature describes combining a DMT-containing plant source with Banisteriopsis caapi, which contains β-carboline alkaloids that inhibit MAO-A. That inhibition is the standard scientific explanation for why DMT in the brew can be orally active: first-pass metabolism of DMT is reduced when MAO-A is inhibited.
This site states that relationship only as chemistry/history. We do not provide plant ratios, brew steps, timing protocols, or any instruction set that could be followed as a preparation guide. If you need the cultural or scientific literature, search peer-reviewed ethnopharmacology and pharmacology reviews — not instruction blogs.
Related educational pages:
- Legal status of DMT / ayahuasca / religious exemptions: legal status
- Molecule vs brew distinctions: DMT vs 5-MeO-DMT
Dependence, tolerance, and risk (what “not classically addictive” does not mean)
Reviews of classic serotonergic psychedelics often note a lack of classical physical dependence (withdrawal syndromes of the opioid/alcohol type) for compounds in this class. That statement is frequently true in the literature and still misleads if read as “harmless.”
Documented risk categories (details and resource links on harm reduction):
- Cardiovascular stress (blood pressure and heart rate changes; especially discussed for 5-MeO-DMT in toxicology and case literature)
- Psychological adverse events (panic, prolonged distress, rare precipitation of psychosis-spectrum crises in vulnerable people)
- Dangerous drug–drug interactions, especially serotonergic combinations (SSRIs/SNRIs, MAOIs, lithium, and related agents) — framed here as why combinations can be dangerous, not as a use protocol
- HPPD and other rare persistent perceptual phenomena reported after hallucinogen exposure in general
No dependence claim on this site is an invitation to use. There is no FDA-approved medical product for either compound for general clinical use as of 2026-07-21.
What this page deliberately omits
| Topic | Why omitted |
|---|---|
| Dose amounts / “threshold / common / strong” charts | Instructional; out of scope |
| Route-of-administration how-tos | Instructional; out of scope |
| Extraction, synthesis, toad secretion collection | Facilitates illegal production; conservation harm |
| “Stacking” or combination schedules | Interaction risk + instruction |
Sources (checked 2026-07-21)
- Nichols DE. Psychedelics. Pharmacological Reviews (review of classical psychedelic pharmacology; receptor-class overview).
- Strassman RJ et al. Dose-response study of N,N-dimethyltryptamine in humans (1990s University of New Mexico IV DMT series; primary human pharmacology).
- Timmermann C et al. Neural correlates of the DMT experience (Sci Rep 2019; later continuous-infusion / imaging work 2023).
- DEA / eCFR Schedule I listings for DMT and 5-MeO-DMT (legal context for research-only access).
- Ethnopharmacology reviews of ayahuasca (MAO-A / β-carboline + DMT interaction as explanatory science).
Last editorial check: 2026-07-21. Educational pharmacology only. Not medical advice.